Letolizumab  (Synonyms: BMS-986004)

Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time^[1][2][3].

[G1 VH-h-CH2-CH3]-dimer

Humanized

Letolizumab inhibits the viability of CD40L trimer and CHO-CD40L in human B cell (IC₅₀ values of 3.6 nM and 1.3 nM, respectively) or nonhuman primate B cell (IC₅₀ values of 3.8 nM and 7.3 nM, respectively)^[2].
Letolizumab (2, 10 and 20 mg/kg; i.v.; once a week for 10 weeks) prolongs the survival time of rhesus macaques after renal transplantation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1450981-87-9

Liquid

Colorless to light yellow

[Letolizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [G1 VH-h-CH2-CH3]-dimer

• [1]. Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103.  [Content Brief]

  [2]. Kim SC, et al. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. Am J Transplant. 2017 May;17(5):1182-1192.  [Content Brief]

  [3]. Spicer P, et al. Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. Expert Opin Investig Drugs. 2019 Feb;28(2):99-106.  [Content Brief]